Abstract 86P
Background
BRAF mutations are found in 1–8% of NSCLC patients (pts), primarily in lung adenocarcinomas. BRAFV600E is the most common variant. Due to its rarity, the clinical characteristics and treatment (trt) practices for pts with BRAFV600E mutant (BRAFMT) mNSCLC are often not well described.
Methods
OCTOPUS is an ongoing multicentre, observational, descriptive, ambispective European study in adults with BRAFMT mNSCLC from Germany, France, Italy, Spain, and the UK, who initiated either a 1st systemic trt in the metastatic setting from 01 Dec 2017 and prior to study entry for retrospective cohort (152 pts) and from 5 July 2022 until 31 January 2024 for prospective cohort (14 pts). This interim analysis for the retrospective cohort outlines pts characteristics, BRAF testing practices, trt patterns, and real-world progression-free survival (rwPFS) for the 1st line of treatment (1st LoT).
Results
152 pts were included retrospectively, median age was 70y (44.0–90.0) at diagnosis of metastatic disease, 53.9% were male. 51.4% were previous smokers, 21.5% current smokers, and 27.1% never-smokers. At the start of 1st LoT 78.5% pts had an ECOG of 0/1. At diagnosis 86.9%were TNM IV and 15.7% had brain metastases. Most pts (95.2%) underwent PD-L1 testing. The tumour proportion score was ≥50% in 44.2%, between 1%–49% in 42.0%, and
Conclusions
In this large EU database of pts with BRAFMT mNSCLC, it was observed that these pts share a similar clinical profile to those without oncogenic-driven tumours including similar median age, majority of male, and a history of current or former smoking. Less than half received a 2nd LoT showing the aggressive nature of the disease. Despite available BRAF and MEK inhibitors, nearly 25% of pts never had TT.
Clinical trial identification
NCT05546905.
Legal entity responsible for the study
Pierre Fabre Laboratories.
Funding
Pierre Fabre Laboratories.
Disclosure
D. Planchard: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Samsung, Celgene, AbbVie, Daiichi Sankyo, Janssen, Seagen, Gilead, Pierre Fabre; Financial Interests, Personal, Invited Speaker: AstraZeneca, Novartis, Pfizer, priME Oncology, Peer CME, Samsung, AbbVie, Janssen, Gilead, Seagen; Non-Financial Interests, Personal, Principal Investigator, Institutional financial interests: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Daiichi Sankyo, Sanofi-Aventis, Pierre Fabre, AbbVie, Sanofi, Janssen. S. Couraud: Financial Interests, Institutional, Funding: Adene, BD Bioscience, Celgene, Chugai, Janssen, Lilly, Takeda, Transdiag, Volition; Financial Interests, Personal and Institutional, Funding: Amgen, AstraZeneca, BMS, Boehringer, MSD, Novartis, Pfizer, Roche, Sanofi; Financial Interests, Personal, Funding: Health Event, Maat Pharma, Pierre Fabre; Non-Financial Interests, Personal, Leadership Role: National guidelines in thoracic oncology (ARISTOT); Non-Financial Interests, Personal, Member of Board of Directors: Société de Pneumologie de Langue Fran,çaise, Adene. C. Mascaux: Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, Bristol Myers Squibb, Pfizer, MSD, Amgen, Janssens; Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, Roche, Bristol Myers Squibb, Pfizer, Kephren, Janssens, Takeda, Sanofi, Novartis. J.B. Auliac: Financial Interests, Personal, Other, scientific meetings, speaking, organizing research, or consulting: Boehringer Ingelheim, Hoffman-Roche, Takeda, BMS, MSD, AstraZeneca, Amgen, and Pfizer. L. Bonomi: Financial Interests, Personal, Other, Honoraria: Bristol Myers Squibb/Celgene, MSD Oncology, AstraZeneca, Astellas Pharma, Janssen Oncology; Financial Interests, Personal, Advisory Role: Janssen Oncology, Ipsen, Roche. E. Carcereny: Financial Interests, Personal, Invited Speaker: Takeda, MSD, AstraZeneca; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Institutional, Research Grant: merk. E. Pons-Tostivint: Financial Interests, Personal, Advisory Board: AstraZeneca, Takeda, BMS, Sanofi, Roche, Daichi Sankyo; Financial Interests, Institutional, Invited Speaker: AstraZeneca, BMS, Daiichi Sankyo, Sanofi, PDC line, Takeda, Amgen. D. Signorelli: Financial Interests, Personal, Other, personal fees: AstraZeneca, Merck Sharp and Dohme, Boehringer Ingelheim, BMS, Roche and Sanofi. F. Beghdad: Financial Interests, Personal, Full or part-time Employment: Pierre Fabre Laboratories. O. Dialla: Financial Interests, Personal, Full or part-time Employment: Pierre Fabre Laboratories. S. Khan: Financial Interests, Personal, Full or part-time Employment: Pierre Fabre Laboratories. S. Popat: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, Novartis, Amgen, Janssen, Daiichi Sankyo, AstraZeneca, Bayer, BMS, Blueprint, Guardant Health, Takeda, Lilly, Turning Point Therapeutics, GSK, MSD, Pfizer, Sanofi, EQRx, AnHeart, Arcus Biosciences, Ellipses, Gilead, IO Biotech, Mirati; Financial Interests, Personal, Expert Testimony: Merck Serono, Roche; Financial Interests, Personal, Invited Speaker: Medscape, VJ Oncology, Novocure, PharmaMar; Financial Interests, Institutional, Other, Sub-investigator: Amgen; Financial Interests, Institutional, Invited Speaker: Ariad, AstraZeneca, Roche, Boehringer Ingelheim, Celgene, Daiichi Sankyo, GSK, Takeda, Trizel, Turning Point Therapeutics, Roche, Janssen, BMS, Lilly; Financial Interests, Institutional, Other, Sub-Investigator: MSD, Blueprint; Financial Interests, Institutional, Research Grant: Guardant Health; Non-Financial Interests, Personal, Leadership Role, Chair of Steering Committee, Unpaid: British Thoracic Oncology Group; Non-Financial Interests, Personal, Officer, Thoracic Faculty, Unpaid: European Society of Medical Oncology; Non-Financial Interests, Personal, Leadership Role, Foundation Council Member, Unpaid: European Thoracic Oncology Platform; Non-Financial Interests, Personal, Advisory Role, Mesothelioma Committee, Unpaid: International Association for the Study of Lung Cancer; Non-Financial Interests, Personal, Member of Board of Directors, Unpaid: Mesothelioma Applied Research Foundation; Non-Financial Interests, Personal, Advisory Role, Honorary Clinical Advisor, Unpaid: ALK Positive UK; Non-Financial Interests, Personal, Advisory Role, Research Advisory Group Member, Unpaid: Ruth Strauss Foundation; Non-Financial Interests, Personal, Advisory Role, Scientific Adivsory Board Member, Unpaid: Lung Cancer Europe. All other authors have declared no conflicts of interest.